← Eichor
Study identifier: NCT06422338 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Rapid Triage Test to Improve Risk-stratification of Febrile Children (EChiLiBRiST, Clinical Trial 1, Outpatients)

Condition: Infectious Disease · Febrile Illness · Child, Only  ·  Sponsor: Barcelona Institute for Global Health

PhaseNA
Planned participants5212
Who can joinAll sexes, 2 Months to 60 Months
Healthy volunteersNo

About this study

The overall aim of the study is to provide evidence that introducing novel biomarkers evaluation at triaging (first clinical assessment), in combination with IMCI-based guidelines (SoC), is a viable strategy to enhance rapid and accurate identification of febrile children at increased risk of life-threatening infections compared to IMCI-based strategies alone (SoC), and to demonstrate whether this results in enhanced decisions of admission/referral vs discharge, and enhanced overall health outcome of children with acute fever in sub-Saharan Africa.

This description comes directly from the study's public registry record.

Talk to the study team

Quique Bassat, Prof  ·  93 227 92 12  ·  quique.bassat@isglobal.org

Barbara Baro, PhD  ·  93 227 92 12  ·  Barbara.baro@isglobal.org

Always discuss trial participation with your own doctor first.

Locations (2)

CERMEL Centre de Recherches Médicales de LambarénéLambaréné, Moyen-Ogooué Province, GabonRecruiting
Mopeia Sede Health CentreMopeia, MozambiqueRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06422338